Gyre Therapeutics, Inc. GYRE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $11.82M+114% | $8.74M+111% | $11.7M+115% | ||
| $2.62M+56.9% | $2.48M+60.2% | $2.29M+64.9% | $2.08M+83.8% | $1.67M+37.6% | ||
| $9.23M+596% | $7.16M+761% | $3.13M-56.3% | $2.22M-68.4% | $1.33M-81.3% | ||
| —— | —— | $3.88M— | —— | —— | ||
| $1.25M-45.1% | $1.19M-50.0% | $1.05M-77.8% | $1.07M-82.1% | $2.27M-67.6% | ||
| —— | —— | -$4.33M+75.8% | -$5.47M+73.8% | -$10.7M+48.3% | ||
| $23.06M+727% | $24.38M+1,060% | $25.02M+52.8% | $24.98M+71.4% | $2.79M-74.5% | ||
| —— | —— | $24.54M+340% | $20.39M+367% | -$14.74M-998% | ||
| $3.07M— | -$180K— | $2.9M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gyre Therapeutics, Inc. generate?
- Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
- What is Gyre Therapeutics, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
- Where does Gyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
